<p>This is a phase 2 multicenter interventional trial involving the preoperative (neoadjuvant) administration of pembrolizumab, an anti-programmed cell death protein-1 (anti-PD-1) agent, to patients with pathologically confirmed, surgically resectable advanced  head and neck squamous cell carcinoma (HNSCC). Participating centers were Dana-Farber/Harvard Cancer Center, Alvin J. Siteman Cancer Center,</p>

Genomic Analyses in Neoadjuvant Immunotherapy-Treated Head and Neck    Cancers

Squamous Cell Carcinoma of Head and Neck study with RNA-Seq, Targeted-Capture + 1 more data on dbGaP (31 participants)